Clinical benefits of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors for unresectable hepatocellular carcinoma

doi:10.4251/wjgo.v16.i7.3308

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (126)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-2) series.

Item

Count

PDF

HTML

Figures (1-4)

Tables (1-2)

Sum=113

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=6

Jul 15, 2024 (publication date) through Jul 15, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Gastrointest Oncol. Jul 15, 2024; 16(7): 3308-3320
Published online Jul 15, 2024. doi: 10.4251/wjgo.v16.i7.3308

Table 2 Ongoing clinical trials for triple therapy

Combination regimen	Comparator	Cancer stage	NCT number	Phase	Primary endpoint
TACE + lenvatinib + sintilimab/camrelizumab	None	Advanced unresectable HCC	NCT04997850	Ⅰ/Ⅱ	Conversion resection rate
TACE + lenvatinib + ICIs	None	Intermediate/advanced HCC	NCT04974281	Ⅰ	Conversion resection rate
TACE + donafenib + ICIs	None	Advanced HCC	NCT05262959	Ⅱ	PFS
TACE + sorafenib + ICIs	None	Intermediate/advanced HCC	NCT04518852	Ⅱ	ORR, OS
TACE + sorafenib + tilelizumab	None	Advanced HCC	NCT04992143	Ⅱ	1-yr survival rate
TACE + lenvatinib + tislelizumab	None	Advanced unresectable HCC	NCT05131698	Ⅰ	ORR
TACE + sorafenib + tilelizumab	None	Advanced HCC	NCT04599777	Ⅱ	OS
TACE + lenvatinib + durvalumab + tremelimumab	TACE	Locoregional HCC not amenable to curative therapy	NCT05301842	Ⅲ	PFS
TACE + lenvatinib + pembrolizumab	TACE	Incurable/Non-metastatic HCC	NCT04246177	Ⅲ	PFS, OS

PFS: Progression-free survival; OS: Overall survival; ORR: Objective response rate; HCC: Hepatocellular carcinoma; TACE: Transarterial chemoembolization; ICI: Immune checkpoint inhibitor.

Citation: Han F, Wang XH, Xu CZ. Clinical benefits of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors for unresectable hepatocellular carcinoma. World J Gastrointest Oncol 2024; 16(7): 3308-3320
URL: https://www.wjgnet.com/1948-5204/full/v16/i7/3308.htm
DOI: https://dx.doi.org/10.4251/wjgo.v16.i7.3308